LITS · Lite Strategy Inc
United States · RS rating 41 · As of 2026-11-03
| Price | 1.04 USD |
|---|---|
| 1-day change | +7.2% |
| RS rating (overall / 1M / 3M / 12M) | 41 / 16 / 80 / 21 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 20 / 30 / 6 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -583.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +54.0% |
| Market cap (USD) | $42.9M |